4.7 Editorial Material

Complement inhibitor for therapy of CHAPLE

Related references

Note: Only part of the references are listed.
Article Immunology

Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease

Ahmet Ozen et al.

Summary: CHAPLE disease is a lethal syndrome caused by genetic loss of the complement regulatory protein CD55. Blocking C5 complement activation with eculizumab can reduce gastrointestinal pathology and restore normal immunity and growth in patients with CHAPLE disease.

NATURE IMMUNOLOGY (2021)

Article Multidisciplinary Sciences

Complement genes contribute sex-biased vulnerability in diverse disorders

Nolan Kamitaki et al.

NATURE (2020)

Review Immunology

Beyond the Role of CD55 as a Complement Component

So Hee Dho et al.

IMMUNE NETWORK (2018)

Article Medicine, General & Internal

CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis

Ahmet Ozen et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)